A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines

Åsmund Flobak1,2,5*, Barbara Niederdorfer1,5, Vu To Nakstad3, Liv Thommesen4,6, Geir Klinkenberg3,6 & Astrid Lægreid1,6

While there is a high interest in drug combinations in cancer therapy, openly accessible datasets for drug combination responses are sparse. Here we present a dataset comprising 171 pairwise combinations of 19 individual drugs targeting signal transduction mechanisms across eight cancer cell lines, where the effect of each drug and drug combination is reported as cell viability assessed by metabolic activity. Drugs are chosen by their capacity to specifically interfere with well-known signal transduction mechanisms. Signalling processes targeted by the drugs include PI3K/AKT, NFkB, JAK/STAT, CTNNB1/TCF, and MAPK pathways. Drug combinations are classified as synergistic based on the Bliss independence synergy metrics. The data identifies combinations that synergistically reduce cancer cell viability and that can be of interest for further pre-clinical investigations.

Background & Summary

Treatment of non-resectable cancer has previously mainly relied on cytotoxic chemotherapy that indiscriminately kills all rapidly dividing cells. With the discovery of molecular mechanisms driving cancer, a new generation of molecularly targeted drugs has entered the market over the last two decades. A remaining challenge in the envisaged transition from ‘one-size-fits all’ therapeutic approach to personalised treatment is the development of resistance to single-targeted drug treatment. Combinatorial therapy may be able to overcome this by co-targeting multiple mechanisms involved in cancer cell growth and survival.

Already compelling results have been achieved with some combinations of cancer signalling inhibitors, e.g. the synergistic combination of MAP2K1/2 (MEK) and BRAF inhibitors for malignant melanoma3–5 and lung adenocarcinoma6. This has sparked a wide interest in identifying novel efficient pairs of small molecule targeted drugs. However, our knowledge about beneficial targeted drug combinations is still limited, partly due to the combinatorial complexity.

Few high-throughput screens testing multiple targeted drugs in combinations have been published with open access data. Examples include combinatorial screens on ovarian cancer cell lines7, melanoma cell lines8, sarcoma cell lines9 and lung-cancer-patient-derived cell culture models10. In a study performed by O’Neil et al., combinations of around 12 targeted drugs were screened across a panel of 39 cancer cell lines. In total 22 experimental drugs were tested in all possible combinations and in combination with 16 approved drugs11. The National Cancer Institute (NCI) screened pairs of 104 FDA-approved cancer drugs against the NCI-60 cell line panel. Around 30 of the tested compounds can be classified as small molecule targeted drugs. However, our knowledge about beneficial targeted drug combinations is still limited, partly due to the combinatorial complexity.

In the AstraZeneca’s drug combination data set of the latest DREAM challenge, 118 drugs, including 59 targeted therapies, were tested in 910 pairwise combinations against 85 cancer cell lines13.

1Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. 2The Cancer Clinic, St. Olav’s Hospital, Trondheim, Norway. 3SINTEF Materials and Chemistry, Department of Biotechnology, Trondheim, Norway. 4Department of Biomedical Laboratory Science, Norwegian University of Science and Technology, Trondheim, Norway. 5These authors contributed equally: Åsmund Flobak and Barbara Niederdorfer. 6These authors jointly supervised this work: Liv Thommesen, Geir Klinkenberg and Astrid Lægreid. *email: asmund.flobak@ntnu.no
In this paper, we report results from a high-throughput screen testing the effects of combining 19 small-molecule inhibitors on cancer cell viability. The drugs target signalling proteins involved in several well described signalling pathways, including PI3K/AKT, NFκB, JAK/STAT, CTNNB1/TCF, and MAPK pathways. Inhibitors were selected for high specificity and a minimum of known off-target activities, as judged from characterizations available from the MRC PPU lab (https://www.ppu.mrc.ac.uk/)\(^4\) for 15 of 19 drugs. Eight cancer cell lines were treated with single inhibitors and 171 pairwise combinations at equimolar concentrations from 10–0.16 µM. Cell viability was determined after 48 hours from ATP content using CellTiter-Glo 2.0 (Promega). Several of the synergistic combinations involved the PI-103 inhibitor. Six of these combinations were investigated in a secondary screen. We here applied a matrix design allowing for synergy assessment outside the equimolar range and determined inhibitor effects from both viability (ATP content) and cell confluency (brightfield imaging). Figure 1 gives a schematic overview of the study design.

In the here presented dataset we rediscovered previously reported synergistic combinations and discovered several new synergies. The synergistic reduction of cell viability resulting from jointly targeting PI3K/mTOR and TAK1, previously reported by us for the AGS cell line\(^15\) and later by others\(^16\), is observed in two of the tested cell lines. Furthermore, we rediscovered the synergistic effect of jointly targeting MEK and PI3K\(^17–20\). Recently, Sathe et al.\(^21\) have reported on increased effect of combined inhibition of PI3K/mTOR and PDPK1 in bladder carcinoma cells.\(^22\) We identify that combined targeting of PI3K/mTOR and PDPK1 is potent across multiple cancer cell lines. The PI3 kinase is one of the canonical activators of PDPK1, and our dataset thus identifies this ‘vertical synergy’ intervention by targeting multiple points in one cascade as a potential chemical intervention for inhibiting PI3K-dependent cancer growth across cell line models representing different tissue types. Co-targeting of multiple vertical points in one cascade is also the rationale for the clinically verified ‘vertical synergy’ observed by jointly targeting MEK and BRAF\(^3–6\). Moreover, PI3K and PI3K/mTOR inhibitors tested in a clinical setting (e.g. pictilisib\(^25\) and apitolisib\(^25\)) have suffered from toxic effects\(^23,24\). Thus, identification of compounds that increase the therapeutic index for PI3K inhibitors could enable new uses for PI3K inhibition in oncology.

The outcomes of our work contribute to expanding the available data sets on novel combinations of targeted drugs across a variety of cancer cell lines and can benefit the fields of cancer therapeutics, molecular signalling interventions and molecular cancer biology.

**Methods**

**Cell lines and culturing.** The following eight cancer cell lines were used in this study: A498 (kidney cancer), AGS (gastric adenocarcinoma), COLO 205 (colorectal cancer), DU-145 (prostate cancer), MDA-MB-468 (breast cancer), SF-295 (glioblastoma), SW-620 (colorectal cancer), and UACC-62 (melanoma). All cell lines used in the study are of human origin. Seven of the cell lines were obtained from the NCI-DCTD Repository, Frederick MD, and are part of the DTP 60 cell line panel (NCI-60 collection). The AGS cell line was obtained from ATCC. AGS cells were cultured in HAMS’s F12 (GIBCO, 21765-029) supplemented with 10% FBS (GIBCO, 10270-106), 10 µg/ml penicillin-streptomycin (GIBCO, 15140-122) and 1 µg/ml fungizone (GIBCO, A1138-03). MDA-MB-468 were cultured in RPMI 1640 (GIBCO, 31870-020) supplemented with 5% FBS (SIGMA, F7524), 2 mM L-Glutamine (SIGMA, G7513) and 100 µg/ml penicillin-streptomycin (GIBCO, 15140-122). All other cells were cultured in RPMI 1640 (GIBCO, 31870-020) supplemented with 10% FBS (SIGMA, F7524), 2 mM L-Glutamine (SIGMA, G7513) and 100 µg/ml penicillin-streptomycin (GIBCO, 15140-122). Cells were cultured for approximately two weeks before assay and discarded after a maximum of two months in culture. The day before seeding out cells for the high throughput assay, cells were sub-cultured 1:2. Due to technical reasons, this was not performed for biological replicate 2 and 3 of the follow-up secondary screen.

**Primary screen - ray designed drug treatment.** Cell lines were treated for 48 hours with 19 small-molecule inhibitors in single and pairwise applications, comprising a total of 171 drug combinations. All
data processing and representation. Viability data - Primary screen. For each 384-well plate, viability data of treated cells was normalised to the DMSO control cells measured in the same plate. Normalised viability data for each biological replicate where processed using “R-script-average-of-biological-replicates.R”. The average viability score for each technical replicate as well as the average viability score across the biological replicates were calculated and exported as tab-separated values (tsv) files. Standard deviation across biological replicates was calculated using “R-script-calculate-mean-STDVR.R”. Dose response curves were generated using “R-script-sensitivity-of-drugs-across-cell-lines-plot.R” (Fig. 2, and in figshare deposit15: Drug_cell_response.pdf). Drug combination plots were generated from average viability scores with standard deviations using
Viability and confluence data - Secondary screen. For confluency data brightfield images were analysed using the SoftMax® Pro Software field analysis setting. For this, the region of the image covering the well was selected and confluency was reported. We note that the absolute values for confluency for very flat and long cells (e.g. A498, SF-295) may be underestimated while absolute confluency for round cells (e.g. MDA-MB-498) may be overestimated. We further want to indicate that COLO 205 are growing sub-confluent. For completeness of the data set, confluency is reported for this cell line. For each 384-well plate, viability and confluency data of treated cells was normalised to the plate-internal DMSO control. Technical replicates and averages of biological replicates are reported as comma-separated files (csv). These were further processed using "Biological_Average_secondary_screen.R" to calculate the biological average, standard deviation and coefficient of variation. Drug combination plots were generation from average viability scores with standard deviations using "Combination_plots_secondary_screen.R" (figshare deposit 25: Combination_plots_secondary_screen_viability.pdf). The same script was used to generate drug combination plots for confluency data (figshare deposit 25: Combination_plots_secondary_screen_confluency.pdf).

Calculation of synergy and statistical significance of quantified synergy. Bliss excess was evaluated for all doses and biological replicates per drug combination and cell line. We first computed all possible Bliss expectations of the reported technical replicates per dose per drug combination. Each technical replicate of combination dose responses was then compared to the average of computed Bliss expectations per technical replicate per dose in same biological replicate. For calculation of Bliss viability values were capped at one.

Bliss excess: viability(drug A + drug B) − viability (drug B) + viability (drug A)

In the primary screen statistical significance of the synergistic response was evaluated. For this the computed Bliss excesses for each drug combination-cell line was compared to a zero-centred normal distribution. T-tests were performed to test for statistically significant deviations from a zero-centred distribution. When the null hypothesis was rejected the alternative hypothesis was accepted, which states that the distribution is not zero-centred, i.e. either antagonistic or synergistic. A conservative Bonferroni correction was done to adjust p values.
values for multiple hypotheses. Combinations with average Bliss excess values $\leq -0.08$ and $p$-value $\leq 0.05$ were classified as synergies. Bliss excess and significance classifications were performed using "p_values_Bliss.R". A synergy score heatmap and volcano plot visualising mean Bliss excess was generated using "R-script-heatmap.R" (Fig. 3a,b). For the secondary screen the average Bliss excesses per dose, combination and cell line were computed using "Bliss_synergy_secondary_screen.R". A cumulative Bliss score was calculated using the same script by taking the mean over the computed Bliss excesses per dose. Combinations with average Bliss excess value $< 0$ were considered as synergies. The lower cut-off was motivated by the fact that five times more combination concentrations were tested in the secondary compared to the primary screen. Example plots of mean Bliss excess $\pm$ standard deviation for two combination tested in the secondary screen are illustrated in Fig. 3c.

**Drug target annotation.** Online-only Table 1 lists inhibitor abbreviation, name and unique identifiers (InChIKey and PubChem CID) along with the provider and primary targets as given by provider. CHEBI IDs are provided when available. We provide extensive target profile information in the form of bioassay information extracted from PubChem (last accessed on 24-06-2019) and kinase profiling data from the MRC PPU International Centre for Kinase Profiling - Kinase Profiling Inhibitor Database (http://www.kinase-screen.mrc.ac.uk/kinase-inhibitors, last time accessed 24-06-2019) available in our figshare deposit.

For the inhibitors SF1670, B605906 and 10058-F4 no bioassay information supporting targets given by the provider were found in PubChem or MRC PPU Inhibitor Database (proteins inhibited below 10% activity). For these inhibitors, we performed an exhaustive literature search to provide annotated information.

**Data Records**

All data is available at figshare, https://doi.org/10.6084/m9.figshare.9810719. Below, the file names for the different data sets are listed.

**Viability and confluency data.** The raw luminescence data from the three biological replicates from the primary screen can be found in NTNU_HTS_Repl[1-3]_raw.txt within figshare. Relative viability data per biological replicate is available in [Cell line].NTNU_HTS_Repl[1-3].processed.tsv. Mean viability data of technical and biological replicates are depicted in [Cell line].tech-mean_Effect.tsv and [Cell line].mean_Effect.tsv. Example plots for drug sensitivity across the eight cell lines are shown in Fig. 2, while all plots can be found in Drug_cell_response.pdf. In Fig. 4, the combination effect of selected drug combinations is visualised. Visualised drug combinations are based on significance and strength of synergy (see section for Calculation of synergy and statistical significance of quantified synergy, Fig. 3). Figure 4b shows average viability of SF-295 cells and A498 cells treated with Doramapimod (B8) in combination with PI-103 (P1), and SF-295 cells treated with BI-D1870 (D1) in combination with PI from the primary and secondary screen. The complete file with all drug combination plots can be found in Combination_plots_primary_screen.pdf for the primary screen and in Combination_plots_secondary_screen_viability.pdf and Combination_plots_secondary_screen_confluency.pdf for the secondary screen for viability and confluency response, respectively.

The raw luminescence data and relative viability data from the three biological replicates from the secondary screen can be found in NTNU_HTS_secondary_viability_REPL[1-3].csv. Raw as well as relative confluency data can be found in NTNU_HTS_secondary_confluency_REPL[1-3].csv. Mean viability and confluency across the three biological replicates are depicted in NTNU_HTS_secondary_viability_Biological_Average.tsv and NTNU_HTS_secondary_confluency_Biological_Average.tsv, respectively.

**Synergy data.** The Bliss excess values for each combination tested in the primary screen across the eight cell lines are represented in bliss_significance.tsv. Synergistic drug combinations are further presented in bliss synergies.tsv. A visual representation of Bliss excess is depicted in Fig. 3a. Cell lines were clustered according to Euclidean distances of quantified synergy strengths. 4% synergies were recorded according Bliss Independence model.

Bliss excess values for each combination per dose tested in the secondary across eight cell lines are represented in bliss_synergies_secondary_screen_viability.tsv and bliss_synergies_secondary_screen_confluency.tsv from viability and confluency data, respectively. A visual representation of Bliss excess $\pm$ standard deviation from the viability data is shown in bliss synergies_secondary_screen_viability_plots_viability.pdf and in bliss synergies_secondary_screen_viability_plots_confluency.pdf from the confluency data. Cumulative bliss scores for the viability data can be found in Mean.Bliss.excess.matrix.tsv.

**Technical Validation**

**Cell line identity.** The seven NCI-cell lines used were received from the NCI-DCTD Repository and cultivated no more than 25 passages after reception in the lab. All cell lines were validated by STR profiling performed by Cell Line Authentication Service at ATCC. Eight core STR loci (TH01, D5S818, D13S317, D7S80, D16S539, CSF1PO, vWA and TPOX) plus amelogenin were matched to database profiles obtained from ATCC and Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ). For two of the cell lines, SF-295 and UACC-62, no database profile was available for comparison from ATCC and DSMZ. However, both cell lines were found to match their STR profile listed on the ExPaSy website (https://web.expasy.org/cellosaurus).

All 7 cell lines were found to be identical or similar to their database profiles with percent matches at 95–100%. The AGS cell line was validated by STR profiling performed by the in-house Genomics Core Facility. Eight core STR loci (TH01, D5S818, D13S317, D7S80, D16S539, CSF1PO, vWA and TPOX) plus amelogenin had a match of 81% to the ATCC profile (CRL-1739).
Viability assay performance and variation. The performance of the viability assays was monitored using a sample set of small molecule positive controls. In the ray design nine concentrations of digitonin ranging from 100 μg/ml to 0.02 μg/ml was included in each biological replicate. In the matrix design a sample set with three concentrations of the positive controls digitonin, ranging from 26 μg/ml to 3 μg/ml, and staurosporine, ranging from 1.6 μM to 0.18 μM, were included in each plate. The standard deviation of the plate internal reference groups was also monitored and was less than 10% at maximum (on average below 5%) in the ray designed screen. Overall, we observed a mean coefficient of variation of 8% across all biological replicates in the primary screen and 7% in the secondary screen for both the viability and confluency data.

To assess reproducibility between biological replicates, we calculated Pearson correlation coefficients for all measured data points (normalised). We observe a high correlation between all comparisons with a correlation of $R = 0.89$ between Replicate 1 vs Replicate 2, $R = 0.88$ between Replicate 1 vs Replicate 3 and $R = 0.87$ between Replicate 2 vs Replicate 3 of the primary screen (See Fig. 5a–c). In the viability data of the secondary screen we
observed a correlation of $R = 0.98$ between Replicate 1 vs Replicate 2, $R = 0.97$ between Replicate 1 vs Replicate 3, and $R = 0.98$ between Replicate 2 vs Replicate 3. In the confluency data of the secondary screen we observed a correlation of $R = 0.90$ between Replicate 1 vs Replicate 2, $R = 0.88$ between Replicate 1 vs Replicate 3, and...
Synergistic combinations in primary screen. The primary screen led to the identification of 55 synergies according to the chosen cut-off from 1368 total combinations for all cell lines. An analysis of the list showed that 23 unique combinations were classified as synergistic across seven unique cell lines, with no synergistic combination in the MDA-MB-468 cell line. The inhibitors PI (targets PIK3CA/B/D, mTOR and DNA-PK) and SF (target PTEN) were identified to be involved in the majority of synergistic combination. The PI inhibitor was identified as synergistic with BI (target MAPK14) and with D1 (target RPS6KA1/2/3/6) in more than half of the tested cell lines. Further synergistic drug pairs sorted by occurrence across cell lines are G2 (target PDPK1), JN (targets MAPK8/9/10), P5 (target SYK) and AK (targets AKT1, AKT2, AKT3).

Synergistic combinations in secondary screen. As the PI inhibitor was identified as one of the top drugs involved in synergistic combinations, it was chosen as the anchor drug for the secondary screen. We combined the PI inhibitor with the top four synergistic drug pairs judged by occurrence across cell lines. We also included PI in combination with PD (targets MAP2K1/2), to investigate synergistic behaviour of drug concentrations outside the concentration ratios tested in the primary screen. This was motivated by the fact that drugs targeting PI3K and MAP2K1/2 have been previously reported to be synergistic in several cell lines. Additionally, we tested PI in combination with 5Z a combination previously identified as synergistic in the AGS cell line in a previous study by our group and Morris et al.

R = 0.95 between Replicate 2 vs Replicate 3. The average viability of shared data points between the primary and secondary screen showed a correlation of R = 0.92 (Fig. 5d). This variation is within the expected variation in high throughput cellular viability assays.

Fig. 5 Scatter plots and computed Pearson correlation values for biological replicates. (a) 1 vs 2, (b) 1 vs 3 and (c) 2 vs 3. The correlation between shared conditions of primary and secondary screen are shown in (d).
Results from the secondary screen confirmed combinations as being synergistic or antagonistic in most cell lines. We confirmed the synergistic effect of PI-G2 in SW-295, SW-620 and UACC-62 cells. Additionally, we observed a synergistic response in A498 and AGS cells in the secondary screen. The combination PI-BI was also re-detected as synergistic in five of the cell lines, while for two cell lines the combination did not show a greater effect compared to single drug treatment in the secondary screen. For two combinations, that were not classified as synergistic in the primary screen, PI-SZ and PI-PD, we could observe synergistic responses in the secondary matrix design screen. The PI-SZ combination was synergistic in two cell lines including AGS cells, confirming previous findings\cite{25,26}. The PI-PD combination (targets PIK3CA/B/D, mTOR and DNA-PK - MAP2K1/2) was found to be synergistic in five cell lines and non-synergistic in three cell lines including the two colorectal cancer cell lines SW-620 and COLO 205. While colorectal cancer cell lines have been frequently observed to display synergistic response to combined inhibition of MAP2K1/2 (MEK1/2) and PI3K\cite{27-30}, weaker synergy has previously been observed in SW-620 and COLO 205 cells\cite{28}.

**Usage Notes**

Other users may investigate alternative methods for synergy quantification or another threshold using the provided data. To assist other researchers in visualising and analysing the dataset from the primary screen described herein we have prepared files that can be uploaded to the web-service Climbinator (http://rbbt.bsc.es/Climbinator/CombinationIndex) from which several synergy metrics can be computed and visualised\cite{22}.

**Code availability**

The data was processed using R 3.5.2 and RStudio Version 1.1.463. The following packages were used for data processing “tidyrr” (0.8.3), “dplyr” (0.8.1), “ggrepel” (0.8.1) and “stats” (3.5.2); and data visualization “RCColorBrewer” (1.1-2), “ggplot2” (3.2.0), “ComplexHeatmap”\cite{32} (1.20.0), “ggpubr” (0.2) and “gridExtra” (2.3).

All code applied for processing and visualising the data is provided at the figshare deposit\cite{24}.

Received: 8 July 2019; Accepted: 7 October 2019;
Published online: 29 October 2019

**References**

1. Al-Lazikani, B., Banerji, U. & Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. *Nat. Biotechnol.* **30**, 679–92 (2012).
2. Senft, D., Leiserson, M. D. M., Ruppin, E. & Ronai, Z. A. Precision Oncology: The Road Ahead. *Trends Mol. Med.* **23**, 874–898 (2017).
3. Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *N. Engl. J. Med.* **371**, 1867–76 (2014).
4. Robert, C. et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. *N. Engl. J. Med.* **372**, 14116004513004 (2014).
5. Long, G. V. et al. Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. *J. Clin. Oncol.* **34**, 871–87 (2016).
6. Planchard, D. et al. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, multicentre phase 2 trial. *Lancet Oncol.* **17**, 984–993 (2016).
7. Au-Yeung, G. et al. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. *Clin. Cancer Res.* **23**, 1862–1874 (2017).
8. Friedman, A. A. et al. Landscape of targeted anti-cancer drug synergies in melanoma identifies a novel BRAF-VEGFR/PDGFR combination treatment. *PLoS One* **10**, 1–21 (2015).
9. Cubitt, C. L. et al. Rapid screening of novel agents for combination therapy in sarcomas. *Sarcoma* **2013** (2013).
10. Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. *Science* **346**, 1480–6 (2014).
11. O’Neill, J. et al. An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies. *Mol. Cancer Ther.* **15**, 1155–62 (2016).
12. Holbeck, S. L. et al. The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. *Cancer Res.* **77**, 3564–3576 (2017).
13. Menden, M. P. et al. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. *Nat. Commun.* **10**, 2674 (2019).
14. Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. *Biochem. J.* **408**, 297–315 (2007).
15. Flouvak, Á. et al. Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling. *PLoS Comput. Biol.* **11**, e1004426 (2015).
16. Morris, M., Clarke, D., Osimiri, L. & Lauffenburger, D. Systematic Analysis of Quantitative Logic Model Ensembles Predicts Drug Combination Effects on Cell Signaling Networks. *CPT Pharmacometrics Syst. Pharmacol.* [https://doi.org/10.1002/psp4.12104](https://doi.org/10.1002/psp4.12104) (2016).
17. Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. *Nat. Med.* **14**, 1351–6 (2008).
18. Hoeflich, K. P. et al. *In vivo* Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models. *Clin. Cancer Res.* **15**, 4649–4664 (2009).
19. Jokinen, E. & Koivunen, J. P. MEK and PI3K inhibition in solid tumors: rationale and evidence to date. *Ther. Adv. Med. Oncol.* **7**, 170–180 (2015).
20. Sathe, A. et al. Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy. *PLoS ONE* **13**, e0190854 (2018).
21. Schoffski, F. et al. A phase Iib study of picitlisib (GDC-0941) in combination with paclitaxel, with and without bevazucizumab or trastuzumab, and with letrozole in advanced breast cancer. *Breast Cancer Res.* **20**, 109 (2018).
22. Powles, T. et al. Randomized Open-Label Phase II Trial of Aripolitinib (GDC-0980), A Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. *J. Clin. Oncol.* **34**, 1660–1668 (2016).
23. Fruman, D. A. et al. The PI3K Pathway in Human Disease. *Cell* **170**, 605–635 (2017).
24. Van De Haar, J. et al. Perspective Identifying Epistasis in Cancer Genomes: A Delicate Affair. *Cell* **177**, 1375–1383 (2019).
25. Flobak, Å. et al. A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines - supplementary table, code, data. Figshare. https://doi.org/10.6084/m9.figshare.9810719.v2 (2019).
26. Iorio, F. et al. A Landscape of Pharmcogenomic Interactions in. Cancer Cell 166, 740–754 (2016).
27. Haagensen, E. J., Kyle, S., Beale, G. S., Maxwell, R. J. & Newell, D. R. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br. J. Cancer 106, 1386–1394 (2012).
28. Clarke, P. A. et al. Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer. Oncogene 38, 5076–5090 (2019).
29. Tosi, D. et al. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment. BMC Cancer 18, 812 (2018).
30. Garcia-Garcia, C. et al. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clin. Cancer Res. 21, 5499–5510 (2015).
31. Flobak, Å., Vazquez, M., Lægreid, A. & Valencia, A. CImbinator: A web-based tool for drug synergy analysis in small-and large-scale datasets. Bioinformatics 33, 2410–2412 (2017).
32. Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics 32, 2847–2849 (2016).

Acknowledgements
We would like to thank Vasundra Touré with providing support for the preparation of the metadata. The work was financed by (1) SINTEF Materials and Chemistry (Project SIP project "Eukaryotic cells"), (2) Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU), and (3) funding from the strategic research area NTNU Health at NTNU, Norwegian University of Science and Technology. The NCI DTP 60 cell lines were provided by the NCI-DCTD Repository in Frederick, MD (MTA 1-5578-1).

Author contributions
Å.F. designed and performed experiments, analysed data and prepared figures. B.N. designed and performed experiments, analysed data, prepared figures and drafted the first version of the manuscript. V.T.N. performed experiments and provided experimental expertise. L.T. and A.L. supervised experiments and provided experimental expertise. G.K. supervised and performed experiments and provided experimental expertise. All authors contributed to writing the final manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to Å.F.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver http://creativecommons.org/publicdomain/zero/1.0/ applies to the metadata files associated with this article.

© The Author(s) 2019